COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies.

Autor: Passamonti F; Dipartimento di Medicina e Chirurgia, Università dell'Insubria, Varese, Italy.; ASST Sette Laghi, Ospedale di Circolo of Varese, Varese, Italy., Romano A; Università degli Studi di Catania, Catania, Italy., Salvini M; ASST Sette Laghi, Ospedale di Circolo of Varese, Varese, Italy., Merli F; Hematology, AUSL-IRCCS, Reggio Emilia, Italy., Porta MGD; Department of Biomedical Sciences, Humanitas Clinical and Research Hospital - IRCCS, Humanitas University, Milano, Italy., Bruna R; Department of Translational Medicine, University of Eastern Piedmont and Ospedale Maggiore della Carità, Novara, Italy., Coviello E; Ospedale Policlinico San Martino-IRCCS, Genova, Italy., Romano I; University of Florence and AOU Careggi, Firenze, Italy., Cairoli R; ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy., Lemoli R; University of Genoa, Genova, Italy., Farina F; San Raffaele, Scientific Institute, Milano, Italy., Venditti A; Ematologia, Dipartimento di Biomedicina e Prevenzione, Università Tor Vergata, Roma, Italy., Busca A; Stem Cell Transplant Center, AOU Citta' della Salute e della Scienza of Torino, Torino, Italy., Ladetto M; Dip di Medicina Traslazionale, Università del Piemonte Orientale ed AO SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy., Massaia M; Santa Croce Hospital, Cuneo, Italy., Pinto A; Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Napoli, Italy., Arcaini L; Division of Hematology, Department of Molecular Medicine, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy., Tafuri A; Department of Clinical and Molecular Medicine, Sapienza, University Hospital Sant'Andrea, University of Rome, Roma, Italy., Marchesi F; Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy., Fracchiolla N; Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy., Bocchia M; Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy., Armiento D; Unit of Hematology, Stem Cell Transplantation, University Campus Bio-Medico, Rome, Italy., Candoni A; Division of Hematology, University Hospital of Udine -ASUFC, Udine, Italy., Krampera M; Department of Medicine, University of Verona, Verona, Italy., Luppi M; Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy., Cardinali V; University of Perugia, Perugia, Italy., Galimberti S; Università di Pisa, Pisa, Italy., Cattaneo C; ASST-Spedali Civili, Brescia, Italy., La Barbera EO; Ospedale Santa Maria Goretti, Latina, Italy., Mina R; Università di Torino, Azienda Ospedaliera Città della Salute e della Scienza, Alessandria, Italy., Lanza F; Santa Maria delle Croci, Ravenna, Italy., Visani G; Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro, Italy., Musto P; Department of Emergency and Organ Transplantation, Unit of Hematology and Stem Cell Transplantation, 'Aldo Moro' University School of Medicine, AOU Consorziale Policlinico, Bari, Italy., Petrucci L; Division of Hematology, Department of Translational and Precison Medicine, Sapienza University of Rome, Rome, Italy., Zaja F; Università di Trieste, Trieste, Italy., Grossi PA; Dipartimento di Medicina e Chirurgia, Università dell'Insubria, Varese, Italy.; ASST Sette Laghi, Ospedale di Circolo of Varese, Varese, Italy., Bertù L; ASST Sette Laghi, Ospedale di Circolo of Varese, Varese, Italy., Pagano L; University Cattolica del Sacro Cuore, Roma, Italy., Corradini P; University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Jazyk: angličtina
Zdroj: British journal of haematology [Br J Haematol] 2021 Nov; Vol. 195 (3), pp. 371-377. Date of Electronic Publication: 2021 Jul 16.
DOI: 10.1111/bjh.17704
Abstrakt: COVID-19 is associated with high mortality in patients with haematological malignancies (HM) and rate of seroconversion is unknown. The ITA-HEMA-COV project (NCT04352556) investigated patterns of seroconversion for SARS-CoV-2 IgG in patients with HMs. A total of 237 patients, SARS-CoV-2 PCR-positive with at least one SARS-CoV-2 IgG test performed during their care, entered the analysis. Among these, 62 (26·2%) had myeloid, 121 (51·1%) lymphoid and 54 (22·8%) plasma cell neoplasms. Overall, 69% of patients (164 of 237) had detectable IgG SARS-CoV-2 serum antibodies. Serologically negative patients (31%, 73 of 237) were evenly distributed across patients with myeloid, lymphoid and plasma cell neoplasms. In the multivariable logistic regression, chemoimmunotherapy [odds ratio (OR), 3·42; 95% confidence interval (CI), 1·04-11·21; P = 0·04] was associated with a lower rate of seroconversion. This effect did not decline after 180 days from treatment withdrawal (OR, 0·35; 95% CI: 0·11-1·13; P = 0·08). This study demonstrates a low rate of seroconversion in HM patients and indicates that treatment-mediated immune dysfunction is the main driver. As a consequence, we expect a low rate of seroconversion after vaccination and thus we suggest testing the efficacy of seroconversion in HM patients.
(© 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: